Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 7/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 7/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11052292 | 0.90 | MAPT (0.58) | RAB9ANPC1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL655375 | 0.88 | HTR7 (0.64) | HTR7RAB9ANPC1PTPN1MAPT | |
| SCHEMBL1269735 | 0.83 | ERCC5 (0.64) | RAB9ANPC1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL11955348 | 0.83 | KMT2A (0.64) | RAB9ANPC1MAPTKMT2AHSD17B10 | |
| SCHEMBL6149922 | 0.83 | RAB9A (0.52) | HTR7RAB9ANPC1PTPN1MAPT | |
| SCHEMBL6061938 | 0.83 | PARP10 (0.58) | RAB9ANPC1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL11485192 | 0.82 | SMN1; SMN2 (0.68) | HTR7RAB9ANPC1PTPN1MAPT | |
| SCHEMBL25081212 | 0.82 | MAOB (0.72) | RAB9ANPC1PTPN1MAPTSMN1; SMN2 | |
| SCHEMBL6142809 | 0.81 | MMP1 (0.59) | RAB9ANPC1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL6142684 | 0.81 | SRD5A2 (0.53) | RAB9ANPC1MAPTHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0986540-B1 | THE USE OF CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AS SODIUM CHANNEL BLOCKERS | EURO CELTIQUE SA (LU) | 2005-02-16 | — | — | EP | claimed |
| US-6696442-B2 | THERAPY OF DISORDER RESPONSIVE TO THE BLOCKADE OF SODIUM CHANNELS IN A MAMMAL SUFFERING THEREFROM BY ADMINISTERING CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES, WHICH ACT AS BLOCKERS OF SODIUM CHANNELS | EURO-CELTIQUE S.A. (LU) | 2004-02-24 | — | — | US | claimed |
| US-RE38425-E1 | ANTICONVULSANTS ADMINISTERED ORALLLY | UNIVERSITY OF SASKATCHEWAN TECHNOLOGIES, INC. (CA) | 2004-02-10 | — | — | US | claimed |
| US-20030225080-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | EURO-CELTIQUES S.A. | 2003-12-04 | — | — | US | claimed |
| US-6613803-B1 | Treating, preventing or ameliorating pain | EURO-CELTIQUE S.A. (LU) | 2003-09-02 | — | — | US | claimed |
| US-20020183321-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | COCENSYS, INC. | 2002-12-05 | — | — | US | claimed |
| US-20020061886-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | COCENSYS, INC. | 2002-05-23 | — | — | US | claimed |
| EP-0836591-B1 | SEMICARBAZONES HAVING CNS ACTIVITY AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME | UNIV SASKATCHEWAN (CA) | 2001-09-26 | — | — | EP | claimed |
| CN-1062263-C | Semicarbazones having CNS activity and pharmaceutical preparations containing same | UNIV SASKATCHEWAN (CA) | 2001-02-21 | — | — | CN | claimed |
| US-5741818-A | ANTICONVULSANTS | UNIVERSITY OF SASKATCHEWAN (CA) | 1998-04-21 | — | — | US | claimed |
| WO-2015117196-A1 | ANTIBACTERIAL AGENTS | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-08-13 | — | — | WO | disclosed |
| EP-1638943-B1 | NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT | SOD CONSEILS RECH APPLIC (FR) | 2008-08-06 | — | — | EP | disclosed |
| CN-1795179-A | Novel imidazole derivatives, the production thereof, and the use of the same as a medicament | SOD CONSEILS RECH APPLIC (FR) | 2006-06-28 | — | — | CN | disclosed |
| EP-1638943-A2 | NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2006-03-29 | — | — | EP | disclosed |
| EP-1568690-A1 | The use of carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones as sodium channel blockers | Euro-Celtique S.A. (LU) | 2005-08-31 | — | — | EP | disclosed |
| US-6613803-B1 | Treating, preventing or ameliorating pain | EURO-CELTIQUE S.A. (LU) | 2003-09-02 | — | — | US | disclosed |
| CN-1422254-A | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | EURO CELTIQUE SA (LU) | 2003-06-04 | — | — | CN | disclosed |
| US-20020183321-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | COCENSYS, INC. | 2002-12-05 | — | — | US | disclosed |
| CN-1353605-A | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and use thereof | EURO CELTIQUE SA (LU) | 2002-06-12 | — | — | CN | disclosed |
| US-20020061886-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | COCENSYS, INC. | 2002-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225080-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | GLRB, SLC1A1, SOD1 | HTR7 2220/4885RAB9A 4389/4885NPC1 1661/4885 |
| US-20020061886-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | GLRB, SLC1A1, SOD1 | HTR7 2220/4885RAB9A 4389/4885NPC1 1661/4885 |
| US-20020183321-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | GLRB, CBR1, ALDH1A2 | HTR7 1869/4885RAB9A 4404/4885NPC1 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.